Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) will present at the 25th Annual Needham Healthcare Conference on Monday, April 13, 2026 at 11:15 am PT / 2:15 pm ET. Management will deliver a fireside chat available via live and archived webcast.
Investors can access the webcast on the company’s Investors website for a live stream and later replay.
Positive
- None.
Negative
- None.
News Market Reaction – SGHT
In the Mar 31 session, SGHT gained 2.45%, reflecting a moderate positive market reaction. Argus tracked a trough of -3.8% from its starting point during tracking.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Earnings results | Positive | -26.8% | Q4 and FY 2025 results with high margins and 2026 guidance issued. |
| Feb 18 | Earnings date notice | Neutral | +4.0% | Announcement of timing for Q4 and full‑year 2025 earnings call. |
| Jan 13 | Preliminary earnings | Neutral | -7.8% | Preliminary Q4 and FY 2025 revenue, dry eye trends, and cash use update. |
| Nov 11 | Clinical data update | Positive | +8.0% | Peer‑reviewed publications on OMNI system showing IOP and med reductions. |
| Nov 06 | Earnings results | Positive | +16.4% | Q3 2025 results with higher margins and raised 2025 revenue guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings-related news has often seen sharp, sometimes negative, price reactions even when fundamentals or guidance improved.
Over the past six months, SGHT has reported several key milestones. Q3 and Q4 2025 earnings showed high gross margins (around mid‑80s%) and reduced operating expenses, with 2026 revenue guidance raised to $82M–$88M. However, the final Q4/FY 2025 report on Mar 4, 2026 led to a ‑26.8% move despite revenue growth in the quarter and guidance. Earlier, peer‑reviewed data for the OMNI system on Nov 11, 2025 coincided with a 7.98% gain, while preliminary 2025 figures on Jan 13, 2026 saw a ‑7.83% reaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually.
Sight Sciences’ management is scheduled to present on Monday, April 13, 2026, at 11:15 am PT / 2:15 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, SION, SmartLids, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
